166 results on '"Ennishi, Daisuke"'
Search Results
2. Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects
3. Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel
4. Clinical significance of gynecological examinations in long-term follow-ups
5. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
6. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
7. Evaluating the efficiency and safety of large‐volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study
8. Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel
9. Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch
10. Long non‐coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B‐cell lymphoma
11. Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide
12. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy
13. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
14. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
15. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
16. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
17. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
18. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
19. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
20. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
21. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
22. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
23. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
24. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
25. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
26. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
27. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
28. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
29. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
30. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
31. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
32. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
33. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
34. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
35. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
36. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
37. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
38. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
39. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
40. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy
41. Prolonged Cytopenia after CAR-T Cell Therapy Is Associated with BM Niche Disruption and a Sustained Inflammation in the BM
42. Pre-infusion factors predicting early failure after tisagenlecleucel for patients with relapsed/refractory diffuse large B-cell lymphoma: A single institute retrospective analysis
43. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML
44. Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation
45. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
46. Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection
47. Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor
48. Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
49. Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
50. Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.